Revolutionizing Mental Health
Compass Pathways plc (CMPS) and Greenbrook TMS Inc (GBNH) have inked an innovative three-year collaboration pact to delve into delivery models for the experimental COMP360 psilocybin treatment.
The research will focus on exploring scalable and commercial COMP360 delivery within healthcare systems, assuming FDA approval.
The initial phase will encompass exploring the delivery of COMP360 at treatment centers across the U.S. catering to individuals contending with treatment-resistant depression (TRD) and other mental health conditions.
COMP360 has earned a “Breakthrough Therapy” designation from the FDA for TRD.
Compass has already launched a phase 3 clinical program of COMP360 in TRD and plans to seek FDA approval upon successful completion of clinical trials.
Striving for Timely Mental Health Solutions
Compass Pathways CEO Kabir Nath emphasized, “Whilst we urgently need more innovative medicines in mental health care, it is just as essential to deliver them at pace to people in greatest need.”
Price Action: CMPS shares are trading lower by 5.52% at $9.08 on the last check Friday.